Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy

American Heart Journal

Volumn 154, Issue 5, 2007, Pages 899-907

  You, John J ^a,f   Woo, Anna ^b,d   Ko, Dennis T ^a,c,d   Cameron, Douglas A ^b,d   Mihailovic, Alexandra ^d   Krahn, Murray ^b,d,e  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d Department of Medicine ^*  (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; HEART DEATH; HYPERTROPHIC CARDIOMYOPATHY; LIFE EXPECTANCY; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MIDDLE AGED; PRIMARY PREVENTION; QUALITY OF LIFE; SURVIVAL RATE;

EID: 35548963414     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.06.026     Document Type: Article

References (56)

1. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 287 (2002) 1308-1320
2. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 42 (2003) 1687-1713
3. Maron B.J., Casey S.A., Poliac L.C., et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281 (1999) 650-655
4. Elliott P.M., Gimeno Jr. B., Mahon N.G., et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357 (2001) 420-424
5. Spirito P., Bellone P., Harris K.M., et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 1778-1785
6. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
7. Maron B.J., Shen W.K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 365-373
8. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death-Executive Summary. Circulation 114 (2006) 1088-1132
9. McKenna W., Deanfield J., Faruqui A., et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 47 (1981) 532-538
10. Hardarson T., De la Calzada C.S., Curiel R., et al. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet 2 (1973) 1462-1467
11. Deaths, by age group and sex, Canada, provinces and territories. Canadian Socio-Economic Information Management System II. Table 1020504. Available at:. http://cansim2/statcan.ca/cgi-win/cnsmcgi.exe?Lang=E&RootDir=CII/ &ResultTemplate=CII/CII___&Array_Pick=1&ArrayId=1020504 [Accessed June 8, 2005]
12. Dennis M.S., Burn J.P., Sandercock P.A., et al. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 24 (1993) 796-800
13. Maron B.J., Olivotto I., Spirito P., et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102 (2000) 858-864
14. Kofflard M.J., Waldstein D.J., Vos J., et al. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol 72 (1993) 939-943
15. Stiell I.G., Wells G.A., DeMaio V.J., et al. Modifiable factors associated with improved cardiac arrest survival in a multicenter basic life support/defibrillation system: OPALS Study Phase I results. Ann Emerg Med 33 (1999) 44-50
16. Owens D.K., Sanders G.D., Harris R.A., et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 126 (1997) 1-12
17. Graves J.R., Herlitz J., Bang A., et al. Survivors of out of hospital cardiac arrest: their prognosis, longevity and functional status. Resuscitation 35 (1997) 117-121
18. Granja C., Cabral G., Pinto A.T., et al. Quality of life 6-months after cardiac arrest. Resuscitation 55 (2002) 37-44
19. Bunch T.J., White R.D., Gersh B.J., et al. Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med 348 (2003) 2626-2633
20. Sanders G.D., Hlatky M.A., Every N.R., et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 135 (2001) 870-883
21. PCD Investigator Group. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: an international multicenter study. J Am Coll Cardiol 23 (1994) 1521-1530
22. Zipes D.P., and Roberts D. Results of the international study of the implantable pacemaker cardioverter-defibrillator. Circulation 92 (1995) 59-65
23. Jayatilleke I., Doolan A., Ingles J., et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 93 (2004) 1192-1194
24. Begley D.A., Mohiddin S.A., Tripodi D., et al. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 26 (2003) 1887-1896
25. Primo J., Geelen P., Brugada J., et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 31 (1998) 1081-1085
26. Mela T., McGovern B.A., Garan H., et al. Long-term infection rates associated with the pectoral versus abdominal approach to cardioverter-defibrillator implants. Am J Cardiol 88 (2001) 750-753
27. McKenna W.J., Harris L., Perez G., et al. Arrhythmia in hypertrophic cardiomyopathy. II: comparison of amiodarone and verapamil in treatment. Br Heart J 46 (1981) 173-178
28. McKenna W.J., Harris L., Rowland E., et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 54 (1984) 802-810
29. McKenna W.J., Oakley C.M., Krikler D.M., et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 53 (1985) 412-416
30. Fananapazir L., Leon M.B., Bonow R.O., et al. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 67 (1991) 169-174
31. Larsen G.C., Manolis A.S., Sonnenberg F.A., et al. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol 19 (1992) 1323-1334
32. Chung F., Barnes N., Allen M., et al. Assessing the burden of respiratory disease in the UK. Respir Med 96 (2002) 963-975
33. Olivotto I., Cecchi F., Casey S.A., et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104 (2001) 2517-2524
34. Eckman M.H., Falk R.H., and Pauker S.G. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med 158 (1998) 1669-1677
35. Catherwood E., Fitzpatrick W.D., Greenberg M.L., et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 130 (1999) 625-636
36. The Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 (1994) 1449-1457
37. The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med 157 (1997) 1237-1240
38. Bell C.M., Chapman R.H., Stone P.W., et al. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making 21 (2001) 288-294
39. Currie C.J., McEwan P., Peters J.R., et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 8 (2005) 581-590
40. Smith K.J., and Pesce R.R. Pulmonary artery catheterization in exacerbations of COPD requiring mechanical ventilation: a cost-effectiveness analysis. Respir Care 39 (1994) 961-967
41. Naglie I.G., and Detsky A.S. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making 12 (1992) 239-249
42. McDonald K.M., Hlatky M.A., Saynina O., et al. Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995. Am Heart J 144 (2002) 413-421
43. Olshansky B., Loots D., and McGrory-Usset M. Implantable cardioverter defibrillator practices and costs at an academic medical center. J Cardiovasc Electrophysiol 12 (2001) 162-166
44. Gold M.R., Froman D., Kavesh N.G., et al. A comparison of pectoral and abdominal transvenous defibrillator implantation: analysis of costs and outcomes. J Interv Card Electrophysiol 2 (1998) 345-349
45. Ferguson Jr. T.B., Ferguson C.L., Crites K., et al. The additional hospital costs generated in the management of complications of pacemaker and defibrillator implantations. J Thorac Cardiovasc Surg 111 (1996) 742-751
46. Miravitlles M., Murio C., Guerrero T., et al. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123 (2003) 784-791
47. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C):S81-9.:S81-S89.
48. Johannesson M., Wikstrand J., Jonsson B., et al. Cost-effectiveness of antihypertensive treatment: metoprolol versus thiazide diuretics. Pharmacoeconomics 3 (1993) 36-44
49. Weinstein M.C., Siegel J.E., Gold M.R., et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276 (1996) 1253-1258
50. Elliott P.M., Sharma S., Varnava A., et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 33 (1999) 1596-1601
51. U.S.Department of Labor BoLS. Consumer Price Index. U.S. Medical Care. CUUR0000SAM. http://www.bls.gov/cpi/home.htm [Accessed June 8, 2005]
52. Wong J.B., Sonnenberg F.A., Salem D.N., et al. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 113 (1990) 852-871
53. Ashraf T., Hay J.W., Pitt B., et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 78 (1996) 409-414
54. Schron E.B., Exner D.V., Yao Q., et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 105 (2002) 589-594
55. Irvine J., Dorian P., Baker B., et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 144 (2002) 282-289
56. Elliott P.M. The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era. Curr Cardiol Rep 3 (2001) 167-172